Citation Impact
Citing Papers
Trained immunity: A program of innate immune memory in health and disease
2016 StandoutScience
Final Version of 2009 AJCC Melanoma Staging and Classification
2009 Standout
Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity
2004 StandoutNobel
Prognostic Significance of Autoimmunity during Treatment of Melanoma with Interferon
2006
Advances in immunotherapy for melanoma
2016
Hallmarks of Cancer: The Next Generation
2011 Standout
Immunotherapy of cancer in 2012
2012
Southwestern Internal Medicine Conference: Clinical Use of Hematopoietic Growth Factors
1993
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
2014 Standout
The treatment of brain metastases in melanoma patients
2004
Inflammation and cancer
2002 StandoutNature
Retinoic acid receptors: From molecular mechanisms to cancer therapy
2014
The Role of Microsatellites as a Prognostic Factor in Primary Malignant Melanoma
2005
Medroxyprogesterone, interferon alfa‐2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis
2007
Prognostic Factors That Determine the Long-Term Survival of Patients with Unresectable Metastatic Melanoma
2008
Chemokines: agents for the immunotherapy of cancer?
2002
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
1996 Standout
Epigenetic therapy of cancer: past, present and future
2006
Cancer immunotherapy: breaking the barriers to harvest the crop
2004 StandoutNobel
Prognostic significance of autoimmunity during treatment of melanoma with interferon
2011
Nanoparticle therapeutics: an emerging treatment modality for cancer
2008 Standout
Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments
2002
Tumor Metastasis: Molecular Insights and Evolving Paradigms
2011 Standout
Phase II evaluation of docetaxel plus one‐day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma
2002
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
2007 Standout
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
2010 Standout
The Epigenomics of Cancer
2007 Standout
Chemotherapy for androgen-independent prostate cancer
2002
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
2007 Standout
Ipilimumab: Unleashing the Power of the Immune System Through CTLA-4 Blockade
2010
Epigenetics in Cancer
2008 Standout
Macrophage Diversity Enhances Tumor Progression and Metastasis
2010 Standout
Dual biological effects of the cytokines interleukin-10 and interferon-γ
2011
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
2004 Standout
Polymer conjugates as anticancer nanomedicines
2006 Standout
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.
1998
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Long-Term Results of a Multi-Institutional Randomized Trial Comparing Prognostic Factors and Surgical Results for Intermediate Thickness Melanomas (1.0 to 4.0 mm)
2000
Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer
2017 StandoutNobel
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
2012
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Safety and Immunogenicity of Tyrosinase DNA Vaccines in Patients with Melanoma
2007
Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?
2011
Histone deacetylases and cancer: causes and therapies
2001 Standout
Improved Endpoints for Cancer Immunotherapy Trials
2010
Gene Silencing in Cancer in Association with Promoter Hypermethylation
2003 Standout
A Single-Institution Validation of the AJCC Staging System for Stage IV Melanoma
2008
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
2015 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
Management of Metastatic Melanoma 2005
2006
The blockade of immune checkpoints in cancer immunotherapy
2012 Standout
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion
2010
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
Genetics and pathogenesis of inflammatory bowel disease
2011 StandoutNature
Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer
2004 Standout
Interleukin-2: Clinical applications
2002
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
2015 StandoutNature
Current strategies in the management of hormone refractory prostate cancer
2003
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
2010 Standout
Macrophage biology in development, homeostasis and disease
2013 StandoutNature
Role of bacillus Calmette–Guérin in the treatment of advanced melanoma
2011
Adjuvant therapy for high‐risk primary and resected metastatic melanoma
2003
Interferon-γ links ultraviolet radiation to melanomagenesis in mice
2011 Nature
Practical Approach to Triple-Negative Breast Cancer
2017
Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials
2008
Structure of the STRA6 receptor for retinol uptake
2016 StandoutScienceNobel
Histone deacetylases (HDACs): characterization of the classical HDAC family
2003 Standout
Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System
2001 Standout
Immune Modulation in Cancer with Antibodies
2013 StandoutNobel
Phase I Trial of Docetaxel With Estramustine in Androgen-Independent Prostate Cancer
1999
SYSTEMIC THERAPY FOR RENAL CELL CARCINOMA
2000
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
Apoptosis in the Pathogenesis and Treatment of Disease
1995 StandoutScience
American Society of Clinical Oncology Recommendations on Fertility Preservation in Cancer Patients
2006 Standout
Durable Complete Responses With High-Dose Bolus Interleukin-2 in Patients With Metastatic Melanoma Who Have Experienced Progression After Biochemotherapy
2007
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
2011 StandoutScience
Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer.
2002
Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment.
2002
Cytokine Storm
2020 Standout
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
2009 Standout
Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma
2010
Palliative Cancer Care a Decade Later: Accomplishments, the Need, Next Steps—From the American Society of Clinical Oncology
2009
pVHL suppresses kinase activity of Akt in a proline-hydroxylation–dependent manner
2016 StandoutScienceNobel
Multistage nanoparticle delivery system for deep penetration into tumor tissue
2011 StandoutNobel
Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer
2003
Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma
2004
Cancer Genome Landscapes
2013 StandoutScience
Pegylated Interferon Alfa-2b Treatment for Patients With Solid Tumors: A Phase I/II Study
2002
Metal–Organic Frameworks in Biomedicine
2011 Standout
Phase II Study of Docetaxel, Estramustine, and Low-Dose Hydrocortisone in Men With Hormone-Refractory Prostate Cancer: A Final Report of CALGB 9780
2001
pH-Operated Nanopistons on the Surfaces of Mesoporous Silica Nanoparticles
2010 StandoutNobel
Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer
2003
A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma.
2013
Targeted therapy for advanced renal cell carcinoma
2008
Phase III Study of Mitoxantrone Plus Low Dose Prednisone Versus Low Dose Prednisone Alone in Patients With Asymptomatic Hormone Refractory Prostate Cancer
2002
Works of Lawrence E. Flaherty being referenced
Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma.
2000
Oral etoposide in the treatment of hormone-refractory prostate cancer
1994
Phase II Trial of Recombinant Human Interleukin-4 in Patients with Disseminated Malignant Melanoma
1998
Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study
2014
Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study.
1998
Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group
2002
SWOG 8825: Melphalan GM-CSF: A phase I study
1992
A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanoma
1990
Weekly 1-hour infusion of paclitaxel
2000
Randomized Trial of Adjuvant Human Interferon Gamma Versus Observation in High-Risk Cutaneous Melanoma: a Southwest Oncology Group Study
1995
A phase III randomized, doúble-blind, multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma
1995
Surgical Adjuvant Active Specific Immunotherapy for Patients with Stage III Melanoma: The Final Analysis of Data from a Phase III, Randomized, Double-Blind, Multicenter Vaccinia Melanoma Oncolysate Trial
1998
A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma
1993
Risk Assessment in Localized Primary Cutaneous Melanoma
2002
Chronic Oral Administration of CI-994: A Phase I Study
2001
Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.
1994
Phase II Trial of Recombinant Interleukin-1β in Patients with Metastatic Renal Cell Carcinoma
1994
Southwest Oncology Group S0008: A Phase III Trial of High-Dose Interferon Alfa-2b Versus Cisplatin, Vinblastine, and Dacarbazine, Plus Interleukin-2 and Interferon in Patients With High-Risk Melanoma—An Intergroup Study of Cancer and Leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group
2014
ACCO: ASCO Core Curriculum Outline
2005
Outpatient Biochemotherapy With Interleukin-2 and Interferon Alfa-2b in Patients With Metastatic Malignant Melanoma: Results of Two Phase II Cytokine Working Group Trials
2001
Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials
2001
Phase II trial of pegylated interferon (Peg-Intron) and thalidomide (Thal) in pretreated metastatic malignant melanoma
2005
Implications of Microscopic Satellites of the Primary and Extracapsular Lymph Node Spread in Patients With High-Risk Melanoma: Pathologic Corollary of Eastern Cooperative Oncology Group Trial E1690
2002
A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: a Southwest Oncology Group study.
1999
Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group
2008
High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190
2000
SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer
2014
Adjuvant Immunotherapy of Resected, Intermediate-Thickness, Node-Negative Melanoma With an Allogeneic Tumor Vaccine: Overall Results of a Randomized Trial of the Southwest Oncology Group
2002
Adjuvant Immunotherapy of Resected, Intermediate-Thickness, Node-Negative Melanoma With an Allogeneic Tumor Vaccine: Impact of HLA Class I Antigen Expression on Outcome
2002
Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma
2004